Literature DB >> 22965887

Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis.

Rakhee Vaidya1, Naseema Gangat, Thitina Jimma, Christy M Finke, Terra L Lasho, Animesh Pardanani, Ayalew Tefferi.   

Abstract

Plasma cytokine milieu is abnormal in primary myelofibrosis (PMF) and correlates with disease phenotype and prognosis. In this study, we show that several plasma cytokines are also abnormally expressed in polycythemia vera (PV; n = 65), compared to normal controls (n = 35), but with a significantly different pattern than that of PMF (n = 127). Direct phenotypic correlation in PV included levels of IL-12 with hematocrit; IL-1b, IL-2, IL-7, FGF-b, and HGF with leukocytosis; and IFN-α and IFN-γ with thrombocytosis. In univariate analysis, levels of 13 cytokines (out of 30 analyzed) correlated with survival but only MIP-1β remained significant on multivariable analysis that included the other cytokines as covariates. Increased level of MIP-1β (P < 0.01), older age (P < 0.01), and leukocytosis (P = 0.03) maintained their association with shortened survival, on multivariable analysis. This study provides preliminary observations that warrant a larger scale study and suggests the value of plasma cytokines as prognostic biomarkers in PV.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965887     DOI: 10.1002/ajh.23295

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  56 in total

Review 1.  Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2020-11-01       Impact factor: 2.929

Review 2.  MicroRNAs in myeloproliferative neoplasms.

Authors:  Huichun Zhan; Christopher Cardozo; Azra Raza
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

3.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Authors:  Georg Greiner; Nadine Witzeneder; Angelika Berger; Klaus Schmetterer; Gregor Eisenwort; Ana-Iris Schiefer; Simone Roos; Theresia Popow-Kraupp; Leonhard Müllauer; Johannes Zuber; Veronika Sexl; Lukas Kenner; Wolfgang R Sperr; Peter Valent; Matthias Mayerhofer; Gregor Hoermann
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

Review 4.  Familial MPN Predisposition.

Authors:  Tsewang Tashi; Sabina Swierczek; Josef T Prchal
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

5.  Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera.

Authors:  Jared S Fowles; Joan How; Maggie J Allen; Stephen T Oh
Journal:  Leukemia       Date:  2019-01-11       Impact factor: 11.528

Review 6.  Novel and emerging therapies for the treatment of polycythemia vera.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Expert Rev Hematol       Date:  2014-10-29       Impact factor: 2.929

Review 7.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

8.  Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.

Authors:  Hew Yeng Lai; Stefan A Brooks; Brianna M Craver; Sarah J Morse; Thanh Kim Nguyen; Nahideh Haghighi; Michael R Garbati; Angela G Fleischman
Journal:  Blood Adv       Date:  2019-01-22

9.  ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Authors:  Stephen T Oh; Moshe Talpaz; Aaron T Gerds; Vikas Gupta; Srdan Verstovsek; Ruben Mesa; Carole B Miller; Candido E Rivera; Angela G Fleischman; Swati Goel; Mark L Heaney; Casey O'Connell; Murat O Arcasoy; Yafeng Zhang; Jun Kawashima; Tomas Ganz; Mark Kowalski; Carrie Baker Brachmann
Journal:  Blood Adv       Date:  2020-09-22

10.  Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.

Authors:  Radhika Gangaraju; Jihyun Song; Soo Jin Kim; Tsewang Tashi; Brandi N Reeves; Krishna M Sundar; Perumal Thiagarajan; Josef T Prchal
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.